MA51334A - Nanoémulgels non aqueux transdermiques pour administration systémique d'inhibiteur de l'aromatase - Google Patents

Nanoémulgels non aqueux transdermiques pour administration systémique d'inhibiteur de l'aromatase

Info

Publication number
MA51334A
MA51334A MA051334A MA51334A MA51334A MA 51334 A MA51334 A MA 51334A MA 051334 A MA051334 A MA 051334A MA 51334 A MA51334 A MA 51334A MA 51334 A MA51334 A MA 51334A
Authority
MA
Morocco
Prior art keywords
nanoemulgels
systemic
aromatase inhibitor
inhibitor delivery
aqueous transdermal
Prior art date
Application number
MA051334A
Other languages
English (en)
Inventor
Assayed Alarabi Nauman Sallam
Husam M Younes
Original Assignee
Univ Qatar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Qatar filed Critical Univ Qatar
Publication of MA51334A publication Critical patent/MA51334A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
MA051334A 2017-12-22 2018-12-19 Nanoémulgels non aqueux transdermiques pour administration systémique d'inhibiteur de l'aromatase MA51334A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762610095P 2017-12-22 2017-12-22

Publications (1)

Publication Number Publication Date
MA51334A true MA51334A (fr) 2020-10-28

Family

ID=66994508

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051334A MA51334A (fr) 2017-12-22 2018-12-19 Nanoémulgels non aqueux transdermiques pour administration systémique d'inhibiteur de l'aromatase

Country Status (4)

Country Link
US (1) US11185504B2 (fr)
EP (1) EP3727363A1 (fr)
MA (1) MA51334A (fr)
WO (1) WO2019123282A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1928399A1 (fr) * 2005-09-26 2008-06-11 L'Oréal Composition et procédé servant à traiter des substrats kératineux avec au moins deux compositions cosmétiques non miscibles
WO2009016064A1 (fr) * 2007-07-31 2009-02-05 Basf Se Utilisation de nanodispersions pour protéger des ingrédients solubles dans l'eau dans des formulations à but cosmétique
JP5902810B2 (ja) * 2011-06-20 2016-04-13 ザ プロクター アンド ギャンブル カンパニー 成形研磨粒子を含むパーソナルケア組成物
AU2014218800C1 (en) 2013-02-22 2017-09-14 Stiefel Laboratories, Inc. Non-aqueous solid stabilized emulsions
WO2016033308A1 (fr) 2014-08-27 2016-03-03 Abbvie Inc. Formulation topique

Also Published As

Publication number Publication date
WO2019123282A1 (fr) 2019-06-27
US20200390701A1 (en) 2020-12-17
US11185504B2 (en) 2021-11-30
EP3727363A1 (fr) 2020-10-28

Similar Documents

Publication Publication Date Title
SI3565550T1 (sl) Farmacevtske sestave, ki vsebujejo meloksikam in rizatriptan
IL275986B (en) Encapsulated cannabinoid formulations for transdermal delivery
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
MA46963A (fr) Méthodes pour déterminer le dosage de céllules car-t
EP3319938A4 (fr) Inhibiteurs à petites molécules de l'oncoprotéine mcl-1 et leurs utilisations
MA47461A (fr) Applicateur de liquide pour administrer des vaccins
EP3325081A4 (fr) Procédés pour l'administration lymphatique de principes actifs
MA43587A (fr) Arnm thérapeutiques codant pour des anticorps anti-ctla-4
MA50533A (fr) Imipridones pour gliomes
EP3405151A4 (fr) Administration transdermique améliorée d'agents actifs
MA50834A (fr) Peptides de pénétration cellulaire pour administration antisens
MA49006A (fr) Inhibiteurs d'ip6k
EP3730126A4 (fr) Composition liquide comprenant un antagoniste du vegf
MA47166A (fr) Polythérapie pour la stéatohépatite non alcoolique (shna) et la fibrose hépatique
IL281357B (en) cd73 inhibitors and their pharmaceutical uses
IL282546A (en) Aerosol formulation
IL283627A (en) Improved transport of large materials
MA41866A (fr) Molécules à auto-assemblage pour l'administration ciblée de médicaments
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
ZA202207967B (en) Pouring device
MA53551A (fr) Dosage nocturne chronique de lasmiditan pour la prévention de la migraine
EP3784237A4 (fr) Dispositif d'administration transdermique de tétrabénazine
FR3020662B1 (fr) Dispositif du type tensionneur pour le serrage et l'avancement controles d'un organe allonge
HK1258449A1 (zh) 伊非曲班治療系統性硬化
GB201817868D0 (en) Aerosolised formulation